Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Sintilimab is a recombinant human monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells. By binding to PD-1, it blocks its interaction with the ligands PD-L1 and PD-L2, thereby inhibiting immune checkpoint signaling and restoring T-cell-mediated immune responses against tumor cells. When combined with chemotherapy agents (such as pemetrexed and platinum-based regimens), this combination has demonstrated improved efficacy in treating advanced cancers—particularly non-small cell lung cancer (NSCLC)—by increasing overall response rates, prolonging progression-free survival (PFS), and overall survival (OS) compared to chemotherapy alone. Sintilimab is developed by Innovent Biologics in partnership with Eli Lilly and marketed under brand names such as Tyvyt in China. It has been approved for several indications including NSCLC, hepatocellular carcinoma, esophageal squamous cell carcinoma, and classical Hodgkin lymphoma[1][3][4][5][6][8].
- Brand names
- Daboshu
- Other names
- sintilimab injectionsintilimab + chemotherapy
02
Targets
DNADNA polymerase familyPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sintilimab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + chemotherapy.